Good morning, everyone, and how are you today? We are doing just fine, despite an unusually busy start. To cope, we are quaffing multiple cups of stimulation to help us along. Perhaps you would like to join us. Remember, no prescription is required, which means there is no need to fuss with coupons or calculating copays and rebates. Meanwhile, here are a few items of interest to get you going. We hope your day is smashing and you conquer the world. And, as always, do keep in touch …

An anonymous donor is paying for a pricey Vertex Pharmaceuticals (VRTX) cystic fibrosis drug for a family whose insurance would not cover the cost for their 3-year-old daughter, The New York Post reports. The company had declined to provide a three-week supply of its Orkambi treatment, which the family could not afford. Justin Kennedy says his insurer refused to pay for the medicine, while the company says his daughter did not meet criteria for providing a so-called bridge supply. His wife’s insurance does not begin until Jan. 1, and he says they cannot afford the $20,000 cost until then.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy